Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Flyer for OBN Digital: Is the UK equity capital market still an attractive listing environment for life science companies?

OBN's expert panel will discuss this issue and consider some of the main questions, including:

  • Is listing on AIM worthwhile?
  • Has MFID II made accessing research on AIM-listed companies harder or easier?
  • What are the advantages of an AIM-listing for fund-raising compared to other markets?
  • How can you choose which market is right or your business?
  • What are the potential downsides?
  • What preparations do you need to make?
  • Do the eligibility requirements pose difficulties for life science companies?


Shawn Manning, Managing Director, Akesios Associates
James Steel, Head Healthcare and Life Sciences Investment Banking Team, Peel Hunt LLP
Andy Smith, Life Sciences Analyst, Equity Development
Chris Searle, Corporate Finance Partner, BDO LLP

About the event:

This session will be run in a live format using Zoom Webinar, with registration open for both OBN Members and Non-Members. 

A live Q&A will follow the keynote presentations and audience members will be encouraged to engage with speakers by sending their questions during the event.

Click here to register